

Resource Summary Report

Generated by [NIF](#) on Aug 3, 2026

Alexa Fluor(R) 700 anti-mouse I-A/I-E

RRID:AB_493727

Type: Antibody

Proper Citation

BioLegend Cat# 107622, RRID:AB_493727

Antibody Information

URL: http://antibodyregistry.org/AB_493727

Proper Citation: BioLegend Cat# 107622, RRID:AB_493727

Target Antigen: I-A/I-E

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC, SB

Antibody Name: Alexa Fluor(R) 700 anti-mouse I-A/I-E

Description: This monoclonal targets I-A/I-E

Target Organism: mouse

Clone ID: Clone M5/114.15.2

Antibody ID: AB_493727

Vendor: BioLegend

Catalog Number: 107622

Alternative Catalog Numbers: 107621

Record Creation Time: 20250820T060711+0000

Record Last Update: 20250820T232008+0000

Ratings and Alerts

No rating or validation information has been found for Alexa Fluor(R) 700 anti-mouse I-A/I-E.

No alerts have been found for Alexa Fluor(R) 700 anti-mouse I-A/I-E.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 111 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Verwaerde S, et al. (2026) Innate type 2 lymphocytes trigger an inflammatory switch in alveolar macrophages. *Immunity*, 59(1), 60.

Avanessian SC, et al. (2026) IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy. *Cancer immunology research*, 14(1), 122.

Zitti B, et al. (2026) Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity. *Immunity*, 59(1), 161.

Wu ZY, et al. (2025) *Alistipes finegoldii* augments the efficacy of immunotherapy against solid tumors. *Cancer cell*, 43(9), 1714.

Eberhard JN, et al. (2025) Immune targeting and host-protective effects of the latent stage of *Toxoplasma gondii*. *Nature microbiology*, 10(4), 992.

Li L, et al. (2025) A bladder-blood immune barrier constituted by suburothelial perivascular macrophages restrains uropathogen dissemination. *Immunity*, 58(3), 568.

Tang Q, et al. (2025) Gut bacterial L-lysine alters metabolism and histone methylation to drive dendritic cell tolerance. *Cell reports*, 44(1), 115125.

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. *Cell reports. Medicine*, 6(2), 101967.

Clark ML, et al. (2025) Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. *Immunity*, 58(7), 1670.

Van Hove H, et al. (2025) Interleukin-34-dependent perivascular macrophages promote vascular function in the brain. *Immunity*, 58(5), 1289.

Ver Heul AM, et al. (2025) RAG suppresses group 2 innate lymphoid cells. *eLife*, 13.

Park R, et al. (2025) CD138 and APRIL regulate plasma cell survival, competition, and retention in the bone marrow niche. *Cell reports*, 44(8), 116123.

Hao Y, et al. (2025) Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition. *Cancer immunology research*, 13(2), 185.

Goggin KE, et al. (2025) Differential Effects of High-Fiber and Low-Fiber Diets on Antitumor Immunity and Colon Tumor Progression in a Murine Model. *Cancer prevention research (Philadelphia, Pa.)*, 18(4), 223.

Frolov A, et al. (2025) Microglia and CD8+ T cell activation precede neuronal loss in a murine model of spastic paraplegia 15. *The Journal of experimental medicine*, 222(7).

Goepp M, et al. (2025) Age-related impairment of intestinal inflammation resolution through an eicosanoid-immune-microbiota axis. *Cell host & microbe*, 33(5), 671.

Mauvais FX, et al. (2025) Metallophilic marginal zone macrophages cross-prime CD8+ T cell-mediated protective immunity against blood-borne tumors. *Immunity*, 58(4), 843.

Reyes EY, et al. (2025) *Cryptococcus* exploits delayed microglial activation, and microglial osteopontin/Spp1 impairs peripheral host control. *Cell host & microbe*, 33(12), 2067.

Mujal AM, et al. (2025) Splenic TNF- α signaling potentiates the innate-to-adaptive transition of antiviral NK cells. *Immunity*, 58(3), 585.

Katkeviciute E, et al. (2025) Bacteria-derived 3-hydroxydodecanoic acid induces a potent anti-tumor immune response via the GPR84 receptor. *Cell reports*, 44(3), 115357.